ArticleCalcified tissue international2022
Resveratrol Promotes Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells Through miR-193a/SIRT7 Axis.
Article in Calcified tissue international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A Systematic Review on the Molecular Mechanisms of Resveratrol in Protecting Against Osteoporosis.International journal of molecular sciences · 2025Pooled it
- Extracellular Vesicles Derived from Resveratrol-Treated BMSCs Promote the Repair of Bone Defects in Osteoporotic Rats.Stem cell reviews and reports · 2026Article
- Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloading.Journal of orthopaedic translation · 2026Article
- Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation.Bone research · 2026Article
- Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.Molecular cancer · 2026Review
- CAPE Derivatives as Potent Agents for Induction of Osteogenic Differentiation in DPSCs and Biomaterial Development.Biomedicines · 2025Article
- Sirtuins in Women's Health.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Polyphenols and Bone Health: A Comprehensive Review of Their Role in Osteoporosis Prevention and Treatment.Molecules (Basel, Switzerland) · 2025Review
- Natural compounds from traditional Chinese medicine regulating stem cell fate: Identification and therapeutic potential.Chinese herbal medicines · 2025Review
- Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Osteoporosis: Causes, Mechanisms, Treatment and Prevention: Role of Dietary Compounds.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Plant molecules reinforce bone repair: Novel insights into phenol-modified bone tissue engineering scaffolds for the treatment of bone defects.Materials today. Bio · 2024Review
- SIRT7: the seventh key to unlocking the mystery of aging.Physiological reviews · 2024Review
- Alternative Medical Therapy.Indian journal of orthopaedics · 2023Review
- Therapeutic approach of natural products that treat osteoporosis by targeting epigenetic modulation.Frontiers in genetics · 2023Review
- Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress.Molecular medicine (Cambridge, Mass.) · 2022Article
- Improving the repair mechanism and miRNA expression profile of tibial defect in rats based on silent information regulator 7 protein analysis of mesenchymal stem cells.Bioengineered · 2022Article
- Systematic Analysis of mRNAs and ncRNAs in BMSCs of Senile Osteoporosis Patients.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol (RES) is a novel dietary phenol compound derived from plants and has been studied extensively for its health benefit and medical potential including osteoporosis. The purpose of this study is to investigate the role of resveratrol in osteoporosis in vivo and in vitro and explore the mechanism of osteogenic differentiation of BMSCs. RT-qPCR, ELISA, and Western blot were used to measure the expression level of miR-193a, SIRT7, and osteogenic markers proteins. The interaction between miR-193a and SIRT7 was validated by dual-luciferase reporter assay. Moreover, MTT assay was conducted to detect cell viability. Alizarin red s staining was used to examine bone formation and calcium deposits. The ovariectomized rat model was set up successfully and HE staining was used to examine femoral trabeculae tissue. Our results showed that miR-193a was overexpressed, while SIRT7 was downregulated in osteoporosis. RES suppressed miR-193a to promote osteogenic differentiation. Mechanically, miR-193a targeted and negative regulated SIRT7. Additionally, it was confirmed that SIRT7 promoted osteogenic differentiation of BMSCs through NF-κB signaling pathway. Further study indicated that RES exerted its beneficial function through miR-193a/SIRT7-mediated NF-κB signaling to alleviate osteoporosis in vivo. Our research suggested that the RES-modulated miR-193a inhibition is responsible for the activation of SIRT7/NF-κB signaling pathway in the process of osteogenic differentiation, providing a novel insight into diagnosis and treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.